Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
337 GBX | -0.88% | -0.30% | +19.08% |
05-14 | Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies | AN |
05-14 | Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+19.08% | 3.68B | |
+33.10% | 709B | |
+30.77% | 595B | |
-1.82% | 367B | |
+20.17% | 334B | |
+5.78% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.22% | 171B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- Transcript : HUTCHMED Limited, 2021 Earnings Call, Mar 03, 2022